Cyclin E transgenic mice: Discovery tools for lung cancer biology, therapy, and prevention

Cancer Prevention Research

Volumn 3, Issue 12, 2010, Pages 1513-1518

  Freemantle, Sarah J ^a   Dmitrovsky, Ethan ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; MICRORNA;

ADENOCARCINOMA; CANCER PREVENTION; CANCER THERAPY; CHROMOSOMAL INSTABILITY; DYSPLASIA; ENZYME DEGRADATION; HEDGEHOG; HYPERPLASIA; LUNG ALVEOLUS CELL TYPE 2; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN E; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC;

EID: 78650318490     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0297     Document Type: Short Survey

References (40)

1. Cancer facts and figures, 2010. Available from: http://www.cancer.org/ acs/groups/content/@nho/documents/document/acspc-024113pdf.
2. Ma Y, Fiering S, Black C, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A 2007;104:4089-94.
3. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res 1999;59:2470-6. (Pubitemid 29242299)
4. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000;60:242-4. (Pubitemid 30070742)
5. Meuwissen R, Berns A. Mouse models for human lung cancer. Genes Dev 2005;19:643-64. (Pubitemid 40395076)
6. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-58.
7. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-309.
8. de Seranno S, Meuwissen R. Progress and applications of mouse models for human lung cancer. Eu Res J 2010;35:426-43.
9. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5.
10. Zhou Y, Rideout WM III, Zi T, et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 2010;28:71-8.
11. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Clin Invest 2009;119:3000-10.
12. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006;20:1496-510. (Pubitemid 43830656)
13. Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280-8.
14. Nagy A, Mar L, Watts G. Creation and use of a cre recombinase transgenic database. Methods Mol Biol 2009;530:365-78.
15. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009;4:1064-72.
16. Volm M, Drings P, Mattern J, Sonka J, Vogt-Moykopf I, Wayss K. Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer 1985;56:1396-403. (Pubitemid 15230589)
17. Testa JR, Siegfried JM. Chromosome abnormalities in human non-small cell lung cancer. Cancer Res 1992;52:2702s-6s.
18. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
19. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300. (Pubitemid 129515546)
20. Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 2004;165:789-800. (Pubitemid 38821970)
21. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
22. Koutsami MK, Tsantoulis PK, Kouloukoussa M, et al. Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression. J Pathol 2006;209:512-21.
23. Tsou MF, Stearns T. Mechanism limiting centrosome duplication to once per cell cycle. Nature 2006;442:947-51. (Pubitemid 44285953)
24. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19 (Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006;103:5947-52.
25. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM. Genetically engineered mouse models in cancer research. Adv Cancer Res 2010;106:113-64.
26. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;11:3974-86. (Pubitemid 40791561)
27. Sargent LM, Senft JR, Lowry DT, et al. Specific chromosomal aberrations in mouse lung adenocarcinoma cell lines detected by spectral karyotyping: a comparison with human lung adenocarcinoma. Cancer Res 2002;62:1152-7.
28. Murga M, Fernandez-Capetillo O. Genomic instability: on the birth and death of cancer. Clin Transl Oncol 2007;9:216-20.
29. Galimberti F, Thompson SL, Liu X, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2010;16:109-20.
30. Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, Duensing S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 2006;25:2943-9. (Pubitemid 43739245)
31. Yuan Z, Goetz JA, Singh S, et al. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene 2007;26:1046-55.
32. Gialmanidis IP, Bravou V, Amanetopoulou SG, Varakis J, Kourea H, Papadaki H. Overexpression of hedgehog pathway molecules and FOXM1 innon-small cell lung carcinomas. Lung Cancer 2009;66:64-74.
33. Chi S, Huang S, Li C, et al. Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett 2006;244:53-60. (Pubitemid 44485862)
34. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003;422:313-7. (Pubitemid 36378358)
35. Ruiz i Altaba A. Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets?Cancer Cell 2008;14:281-3.
36. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008;455:406-10.
37. Liu X, Sempere LF, Galimberti F, et al. Uncovering growth-suppressive microRNAs in lung cancer. Clin Cancer Res 2009;15:1177-83.
38. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9.
39. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
40. Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next?Trends Pharmacol Sci 2008;29:16-21.